ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Invesco Nasdaq Biotechnology ETF
34.36
+0.1059
0.31%
盤後：
34.35
-0.0059
-0.02%
19:59 EDT
成交量：
1.97萬
成交額：
67.75萬
市值：
9,550.94萬
市盈率：
- -
高：
34.62
開：
34.39
低：
34.20
收：
34.25
52周最高：
36.84
52周最低：
23.42
股本：
278.00萬
流通股本：
278.00萬
量比：
0.95
換手率：
0.71%
股息：
0.26
股息率：
0.75%
淨資產收益率：
--
總資產收益率：
--
市淨率：
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
港股概念追蹤 | 創新藥賽道持續升温 AI提效向臨床縱深推進(附概念股)
智通财经
·
09/07
百利天恒：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告
证券日报网
·
09/06
國內首款AI輔助創新藥獲批上市！西湖大學聯合研發 僅用時三年半
快科技
·
09/06
我國首款AI輔助創新藥獲批上市
智通财经
·
09/06
創新藥三大指數上漲、ETF吸金，CXO及科研服務呈高景氣度
环球网
·
09/06
創新藥投資，優先佈局這些可把握的機會
证券市场周刊
·
09/05
復宏漢霖朱儁：未來所有製藥企業都是AI製藥企業，不存在不依賴AI的生物製藥企業
睿见Economy
·
09/05
2026年國家醫保目錄現場談判競價與商保創新藥目錄價格協商在京開啓
智通财经
·
09/05
康寧傑瑞生物製藥回購56,000股 耗資492,430港元
财闻
·
09/04
中國中藥(00570)：1.1類中藥創新藥醒脾解鬱片獲批上市
智通财经
·
09/04
中國中藥：同濟堂製藥1.1類中藥創新藥醒脾解鬱片獲批上市
智通财经
·
09/04
重大臨床突破引爆，康方生物單日飆漲11.45%！港股通創新藥量價齊升，新一輪行情啓動？
新浪基金
·
09/04
復旦張江：公司將於9月16日參加2026年半年度科創板創新藥行業集體業績説明會
证券日报
·
09/04
「該給我個交代！」 易慕峯臨床試驗受試者死亡，董事讓記者「滾開」，15天前啱啱遞表，對話家屬還原經過
BUG
·
09/04
廣生堂：GST-Peak-Triple臨床試驗首例成功入組
智通财经
·
09/04
長春高新(000661.SZ)子公司GenSci133注射液臨床試驗申請獲得批准
智通财经
·
09/04
長春高新：子公司GenSci133注射液臨床試驗申請獲批准
智通财经
·
09/04
中國銀河證券：創新藥產業鏈高景氣 商業化與對外授權變現打開成長空間
智通财经网
·
09/04
創新藥板塊活躍 昂利康漲停
同花顺
·
09/04
更多創新藥有望納入醫保報銷
格隆汇
·
09/04
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/IBBQ/news?page=10"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.3559,"timestamp":1789588800000,"preClose":34.25,"halted":0,"volume":19691,"hourTrading":{"tag":"盘后","latestPrice":34.35,"preClose":34.3559,"latestTime":"19:59 EDT","volume":40,"amount":1379.2795,"timestamp":1789603165220,"change":-0.0059,"changeRate":-0.000172,"amplitude":0},"delay":0,"changeRate":0.003091970802919659,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"未開盤","change":0.1059,"latestTime":"09-16 16:00:00 EDT","open":34.39,"high":34.62,"low":34.1992,"amount":677542.144902,"amplitude":0.012286,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789632000000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":34.25,"sharesOutstanding":2520001,"nav":34.27126,"aum":95274137.07126,"dividendRate":0.007478,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":34.28,"preClose":34.25,"latestTime":"09:29 EDT","volume":69,"amount":2360.8497660000003,"timestamp":1789565397037,"change":0.03,"changeRate":0.000876,"amplitude":0.008175},"postHourTrading":{"tag":"盘后","latestPrice":34.35,"preClose":34.3559,"latestTime":"19:59 EDT","volume":40,"amount":1379.2795,"timestamp":1789603165220,"change":-0.0059,"changeRate":-0.000172,"amplitude":0},"volumeRatio":0.950696,"impliedVol":0.1125,"impliedVolPercentile":0.4741},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.950696,"shares":2780001,"dividePrice":0.2569,"high":34.62,"amplitude":0.012286,"preClose":34.25,"low":34.1992,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.3559,"eps":0,"divideRate":0.007478,"volume":19691,"delay":0,"ttmEps":0,"open":34.39,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":34.9277,"twentyDayClose":34.6197,"sixtyDayClose":30.4995},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:10,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665836774","title":"港股概念追蹤 | 創新藥賽道持續升温 AI提效向臨床縱深推進(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665836774","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665836774?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 06:53","pubTimestamp":1788735233,"startTime":"0","endTime":"0","summary":"西湖大学生命科学学院教授黄晶表示，AI辅助新药研发已不止于概念，而真正可以支撑原创药物从发现走向临床，直至上市。艾普司韦是西湖大学首款完全自主研发的1类创新药，用于成人轻型、中型新型冠状病毒感染的治疗。中国AI制药市场规模2025年已突破6亿元。从经营数据来看，AI相关业务正成为部分企业订单和收入增长的重要驱动力；与此同时，下游药企也在积极拥抱AI，研发提效成果逐步显现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1617","BK1191","IBBQ","BK1161","AGIX","02196","LNGR","ARTY","06978","AIPO","CHAT","BK1141","VTHR","BK4585","BK1515","QTOC","03696","KCAI","BK4588","VXUS","MEDX","BK1593","02228","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665709364","title":"百利天恒：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665709364","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665709364?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 18:31","pubTimestamp":1788690660,"startTime":"0","endTime":"0","summary":"证券日报网讯9月6日，百利天恒发布公告称，公司计划于2026年9月16日15：00-17：00参加科创板2026年半年度创新药行业集体业绩说明会，就投资者关心的问题进行交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-06/doc-iniqwwyu6754784.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-06/doc-iniqwwyu6754784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688506","BK0239","LNGR","91194","BK1574","IBBQ","159992","BK1161","06978","MEDX","KSTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665403361","title":"國內首款AI輔助創新藥獲批上市！西湖大學聯合研發 僅用時三年半","url":"https://stock-news.laohu8.com/highlight/detail?id=2665403361","media":"快科技","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665403361?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 15:30","pubTimestamp":1788679839,"startTime":"0","endTime":"0","summary":"快科技9月6日消息，据西湖大学微信公众号消息，近期，由西湖大学、西湖实验室、西湖制药联合研发的创新药——盐酸伊司特韦片 正式获得国家药品监督管理局附条件批准上市。据悉，它是国内首款凭借AI辅助研发而获批上市的原创药——从源头发现到完成临床试验，仅用时三年半。这也是西湖大学首款完全自主研发的1类创新药，用于成人轻型、中型新型冠状病毒感染的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8wCSabf9QIo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["ARTY","MEDX","IPOS","VTHR","AIPO","BK1161","06978","LNGR","CHAT","159992","IBBQ","QTOC","BK1574","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665361592","title":"我國首款AI輔助創新藥獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2665361592","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665361592?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 15:04","pubTimestamp":1788678281,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","ARTY","AIPO","AGIX","MEDX","VTHR","IPOS","CHAT","QTOC","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665369630","title":"創新藥三大指數上漲、ETF吸金，CXO及科研服務呈高景氣度","url":"https://stock-news.laohu8.com/highlight/detail?id=2665369630","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665369630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 09:57","pubTimestamp":1788659820,"startTime":"0","endTime":"0","summary":"H股创新药指数2026上半年收入同比增长17.91%、归母净利润同比增长60.94%、扣非归母净利润同比增长30.73%。银河证券分析称，上半年行业利润增长显著快于收入，主要系创新药商业化收入及对外授权收入增加，高毛利业务占比大幅提升，同时CXO和科研服务呈高景气度，订单增长驱动前期产能建设和人员储备充分利用，摊薄固定成本并推动利润增长。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-06/doc-iniqvzvc0193188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","FDN","BK4550","BK1574","WX","MEDX","BK4588","BK1161","BK4585","LNGR","159992","06978","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665538368","title":"創新藥投資，優先佈局這些可把握的機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2665538368","media":"证券市场周刊","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665538368?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 14:51","pubTimestamp":1788591110,"startTime":"0","endTime":"0","summary":"当AI行情阶段性休整、市场四处寻找下一条主线之时，创新药板块悄然走出一轮反弹行情。Wind数据显示，2026年6月9日至9月2日，恒生沪深港创新药50指数涨幅达到33.08%，CXO指数涨幅46.07%。但赛道本身波动性也极强。2025年前三季度，部分创新药指数最高涨幅超100%，随后自去年10月开启长达8个月的深度调整，截至2026年5月底，板块最大回撤超过30%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609053866007987.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609053866007987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","06978","BK1574","LNGR","MEDX","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665936888","title":"復宏漢霖朱儁：未來所有製藥企業都是AI製藥企業，不存在不依賴AI的生物製藥企業","url":"https://stock-news.laohu8.com/highlight/detail?id=2665936888","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665936888?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 14:04","pubTimestamp":1788588240,"startTime":"0","endTime":"0","summary":"朱俊坦言，尽管近年来国家批准的创新药数量已领先全球，但临床疗效的提升依然艰难。他强调，如果AI不能进一步赋能，生物医药产业将继续处于原始状态。未来，所有的制药企业都必须是AI制药企业，不存在不依赖AI的生物制药企业。朱俊总认为，在全球变局下，只要企业能够用好AI、抓住精准人群并解决真实的临床痛点，即使十个机会中只能抓住一个，也足以支撑企业的长远发展。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-09-05/doc-iniquccs3668085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000306701.USD","HK0000306685.HKD","02696","03069","HK0000320264.USD","IBBQ","MRNY","AGIX","QTOC","AIPO","BK1161","BBP","BK1191","BK1574","ARTY","HK0000320223.HKD","MRNX","CHAT","VTHR","HK0000165453.HKD","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665352256","title":"2026年國家醫保目錄現場談判競價與商保創新藥目錄價格協商在京開啓","url":"https://stock-news.laohu8.com/highlight/detail?id=2665352256","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665352256?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 08:12","pubTimestamp":1788567172,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LNGR","MEDX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664337721","title":"康寧傑瑞生物製藥回購56,000股 耗資492,430港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664337721","media":"财闻","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664337721?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 20:53","pubTimestamp":1788526380,"startTime":"0","endTime":"0","summary":"9月4日，康宁杰瑞生物制药于2026年9月4日在香港联交所回购56,000股普通股，每股回购价格最高HKD8.8、最低HKD8.75，付出价格总额HKD492,430。回购股份拟持作库存股份，拟注销数目为0。回购后，已发行股份数目由968,056,697股减至968,000,697股，库存股份数目由6,325,000股增至6,381,000股，已发行股份总数维持974,381,697股。此次回购依据2026年6月12日获通过的回购授权进行，该授权可回购股份总数为96,850,669股。回购后暂止期截至2026年10月4日。呈交者为执行董事徐霆。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-04/doc-iniqsrak4001786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","BBP","03069","CNAV","IBBQ","MRNY","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664334496","title":"中國中藥(00570)：1.1類中藥創新藥醒脾解鬱片獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2664334496","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664334496?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 20:50","pubTimestamp":1788526251,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国中药(00570)发布公告，有关国家药监局受理集团的附属公司国药集团同济堂（贵州）制药有限公司（同济堂制药）的1.1类中药创新药郁枢达片注册上市申请。经国家药监局完成技术审评、现场核查、抽样检验等一系列工作程序，同济堂制药申报的1.1类中药创新药醒脾解郁片（即先前公告所称“郁枢达片”，为该药品获国家药监局核准的规范通用名称）已获得批准上市，药品上市许可持有人为同济堂制药。醒脾解郁片具有醒脾化湿、理气解郁的功效，用于轻、中度抑郁症，症状为情绪郁闷、低落，表情淡漠、倦怠乏力、失眠多梦、少气懒言、食少纳呆，头重肢困、 口中黏腻、面色晦暗，舌淡苔白腻或灰腻、脉滑或弦。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1515","BK1606","IBBQ","BK1161","00570","LNGR","MEDX","BK1574","BK1191","IPOS","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664334139","title":"中國中藥：同濟堂製藥1.1類中藥創新藥醒脾解鬱片獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2664334139","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664334139?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 20:48","pubTimestamp":1788526108,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LNGR","IBBQ","IPOS","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664339358","title":"重大臨床突破引爆，康方生物單日飆漲11.45%！港股通創新藥量價齊升，新一輪行情啓動？","url":"https://stock-news.laohu8.com/highlight/detail?id=2664339358","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664339358?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 19:16","pubTimestamp":1788520560,"startTime":"0","endTime":"0","summary":"港股通创新药终于动起来了，9月4日，板块放量三连涨，100%创新药研发标的——港股通创新药ETF华宝成功收复年线外的所有均线。个股方面，康方生物单日暴涨11.45%断层领涨，成为板块情绪绝对龙头。港股通创新药板块受何驱动，新一轮行情开始启动了？文中提及个股在恒生港股通创新药精选指数中的权重占比情况见配图。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-04/doc-iniqskus1177431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0540923850.HKD","LU2476274308.USD","LU1720050803.USD","09926","LU2488822045.USD","LU2476274720.SGD","LU0348827113.USD","LU0561508036.HKD","LU0348825331.USD","LU0348767384.USD","LU1794554557.SGD","IE00B543WZ88.USD","LU0348783233.USD","LNGR","FLHK","IE00B5MMRT66.SGD","KURE","LU0417516902.SGD","159992","LU0348735423.USD","LU0348784397.USD","BK1161","BK1574","06978","LU0417516571.SGD","LU0634319403.HKD","LU0348766576.USD","LU2399975544.HKD","IBBQ","LU0417516738.SGD","LU1961090484.USD","MEDX","IE00BPRC5H50.USD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664339848","title":"復旦張江：公司將於9月16日參加2026年半年度科創板創新藥行業集體業績説明會","url":"https://stock-news.laohu8.com/highlight/detail?id=2664339848","media":"证券日报","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664339848?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 18:54","pubTimestamp":1788519240,"startTime":"0","endTime":"0","summary":"复旦张江：公司将于9月16日参加2026年半年度科创板创新药行业集体业绩说明会","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609043865545454.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609043865545454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK0239","BK1191","LNGR","688505","BK1161","BK1574","159992","01349","MEDX","IBBQ","KSTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664137336","title":"「該給我個交代！」 易慕峯臨床試驗受試者死亡，董事讓記者「滾開」，15天前啱啱遞表，對話家屬還原經過","url":"https://stock-news.laohu8.com/highlight/detail?id=2664137336","media":"BUG","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664137336?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 18:47","pubTimestamp":1788518820,"startTime":"0","endTime":"0","summary":"9月2日，时代周报记者就易慕峰生物科技股份有限公司临床试验受试者死亡事件致电该公司董事李某昕，得到了这样的回应。本次死亡可能属于SAE严重不良事件。后来其丈夫占某签字同意加入这个临床试验。医院与药方对该事件的口径一致，患者脑出血是化疗药物副作用所致，与试验药物无关。程女士反复表示，无法接受医院和药企对占某参加临床试验突然死亡事件的解释。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-04/doc-iniqskus1166780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PSYK","IBBQ","IPOS","BMED","MDTX","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664335039","title":"廣生堂：GST-Peak-Triple臨床試驗首例成功入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2664335039","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664335039?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 18:27","pubTimestamp":1788517656,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","IBBQ","GST","PSYK","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664938709","title":"長春高新(000661.SZ)子公司GenSci133注射液臨床試驗申請獲得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664938709","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664938709?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 16:22","pubTimestamp":1788510145,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)发布公告，近日，公司控股子公司长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，金赛药业GenSci133注射液的境内生产药品注册临床试验申请获得批准。据悉，GenSci133注射液是金赛药业自主研发的一款甲状旁腺激素(PTH)类似物与抗核因子κB受体活化因子配体(RANKL)抗体融合蛋白，属于治疗用生物制品1类，拟用于治疗骨质疏松症。如子公司临床试验申请进展顺利，将有利于公司拓宽业务结构、优化产品结构，并丰富完善内分泌代谢领域产品线布局、提升公司核心竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492053.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0057","BMED","BK0046","BK0188","BK0075","IBBQ","PSYK","BK0239","000661","BK0028","MDTX","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664462387","title":"長春高新：子公司GenSci133注射液臨床試驗申請獲批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664462387","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664462387?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 16:12","pubTimestamp":1788509543,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBJ","IBBQ","MDTX","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238064","title":"中國銀河證券：創新藥產業鏈高景氣 商業化與對外授權變現打開成長空間","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238064","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664238064?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 15:54","pubTimestamp":1788508491,"startTime":"0","endTime":"0","summary":"上半年行业利润增长显著快于收入，主要系创新药商业化收入及对外授权收入增加，高毛利业务占比大幅提升，同时CXO和科研服务呈高景气度，订单增长驱动前期产能建设和人员储备充分利用，摊薄固定成本并推动利润增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0188","BK1147","IBBQ","159992","LNGR","BK1564","06881","601881","06978","MEDX","BK1574","161027","BK1161","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664385956","title":"創新藥板塊活躍 昂利康漲停","url":"https://stock-news.laohu8.com/highlight/detail?id=2664385956","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664385956?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 10:57","pubTimestamp":1788490620,"startTime":"0","endTime":"0","summary":"上证报中国证券网讯(记者冯心怡)9月4日早盘，创新药板块表现活跃，昂利康涨停，报27.86元/股，涨幅为9.99%。昂利康坚持“仿制药—改良型新药—创新药”的研发布局。据新华社9月4日消息，国 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260904/c679599107.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260904/c679599107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["159992","IBBQ","BK1161","MEDX","LNGR","BK0239","002940","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664383252","title":"更多創新藥有望納入醫保報銷","url":"https://stock-news.laohu8.com/highlight/detail?id=2664383252","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664383252?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 10:20","pubTimestamp":1788488426,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","ENTL","HART","IBBQ","IHI","LNGR","MEDX","06978","PSCH","159992","BK1161","BK1574","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":10,"totalSize":219,"code":"91000000","status":"200"}]}}